Aquaporin-4 antibodies in patients treated with natalizumab for suspected MS

Aquaporin-4 antibodies in patients treated with natalizumab for suspected MS

OBJECTIVE To evaluate (1) the frequency of aquaporin-4 antibody (AQP4-ab)-seropositive cases among patients treated with natalizumab (NAT) and previously diagnosed with MS (MSNAT) in a nationwide cohort, (2) the clinical course of NAT-treated AQP4-ab-seropositive neuromyelitis optica spectrum disorder (NMOSD) patients (NMONAT), (3) AQP4-ab titers in NMONAT and AQP4-ab-seropositive NMOSD treated...

Maraviroc as possible treatment for PML-IRIS in natalizumab-treated patients with MS

Progressive multifocal leukoencephalopathy (PML) is a serious complication of natalizumab treatment in patients with relapsing-remittingMS (RRMS) with 638 confirmed cases as of March 2016. Therapeutic reestablishment of cerebral immune surveillance in PML management is complicated by immune reconstitution inflammatory syndrome (IRIS), an exuberant inflammatory response that aggravates damage ca...

Immunological Markers for PML Prediction in MS Patients Treated with Natalizumab

Natalizumab (NTZ), a monoclonal antibody recognizing the alpha4 integrin chain, has been approved for the treatment of active multiple sclerosis, but expose to the onset of a rare side effect, progressive multifocal leukoencephalopathy (PML). Estimating the individual risk of PML in NTZ-treated patients is a major challenge, and therapeutic strategies are mainly guided by the overall PML risk a...

Aquaporin-4 antibody titration in NMO patients treated with rituximab

OBJECTIVE We undertook an observational retrospective study to investigate the usefulness of aquaporin-4 (AQP4) antibodies (Ab) titration in the management of patients with neuromyelitis optica (NMO) treated with rituximab (RTX) by studying (1) the correlation between AQP4-Ab titer and disease activity, (2) the influence of RTX on antibody levels, and (3) the association between AQP4-Ab levels ...

Anti-JC Virus Antibodies in a Large German Natalizumab-Treated MS Cohort.